ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer

RAS gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K and RB pathways. Within the MAPK pathway ERK1/2 proteins exert a bottleneck function for transmitting mitogenic signals and activating cytoplasmic...

Full description

Saved in:
Bibliographic Details
Published in:Mol Cancer Ther
Main Authors: Köhler, Jens, Zhao, Yutong, Li, Jiaqi, Gokhale, Prafulla C., Tiv, Hong L., Knott, Aine R., Wilkens, Margaret K., Soroko, Kara M., Lin, Mika, Ambrogio, Chiara, Musteanu, Monica, Ogino, Atsuko, Choi, Jihyun, Bahcall, Magda, Bertram, Arrien A., Chambers, Emily S., Paweletz, Cloud P., Bhagwat, Shripad V., Manro, Jason R., Tiu, Ramon V., Jänne, Pasi A.
Format: Artigo
Language:Inglês
Published: 2021
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8026682/
https://ncbi.nlm.nih.gov/pubmed/33536188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0531
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items